Skip to main content
Woman in a blue tank top looking down at her hands while standing in front of a mirror in a softly lit room





Patient-reported outcomes 


 

Patient portrayal.

AIS7, activity interference score over 7 days; BID, twice daily; SIS7, sleep interference score over 7 days.

References: 1. Data on file. CSR study. CLOU64A2302. Novartis Pharmaceuticals Corp; November 2024. 2. Metz M, Giménez-Arnau A, Hide M, et al; REMIX-1 and REMIX-2 Investigators. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994. doi:10.1056/NEJMoa2408792